TY  - JOUR
PY  - 2022//
TI  - Rapid treatments for depression: Endocannabinoid system as a therapeutic target
JO  - Neuroscience and biobehavioral reviews
A1  - Sharafi, AmirMohammad
A1  - Pakkhesal, Sina
A1  - Fakhari, Ali
A1  - Khajehnasiri, Nazli
A1  - Ahmadalipour, Ali
SP  - e104635
EP  - e104635
VL  - 137
IS  - 
N2  - Current first-line treatments for major depressive disorder (MDD), i.e., antidepressant drugs and psychotherapy, show delayed onset of therapeutic effect as late as 2-3 weeks or more. In the clinic, the speed of beginning of the actions of antidepressant drugs or other interventions is vital for many reasons. Late-onset means that depression, its related disability, and the potential danger of suicide remain a threat for some patients. There are some rapid-acting antidepressant interventions, such as sleep deprivation, ketamine, acute exercise, which induce a significant response, ranging from a few hours to maximally one week, and most of them share a common characteristic that is the activation of the endocannabinoid (eCB) system. Activation of this system, i.e., augmentation of eCB signaling, appears to have anti-depressant-like actions. This article puts the idea forward that the activation of eCB signaling represents a critical mechanism of rapid-acting therapeutic interventions in MDD, and this system might contribute to the development of novel rapid-acting treatments for MDD.<p /> <p>Language: en</p>
LA  - en
SN  - 0149-7634
UR  - http://dx.doi.org/10.1016/j.neubiorev.2022.104635
ID  - ref1
ER  -